CAMP4 Therapeutics Corporation
CAMP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.19 | 0.27 | 1.32 |
| FCF Yield | -18.55% | -35.38% | -18.67% | -11.34% |
| EV / EBITDA | 0.57 | 0.21 | -2.88 | -3.41 |
| Quality | ||||
| ROIC | -16.10% | -27.65% | -22.04% | -19.55% |
| Gross Margin | 47.67% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 0.82 | 1.15 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -74.48% | -78.47% | -82.77% | -86.82% |
| Free Cash Flow Growth | -8.45% | 28.99% | -26.09% | -19.17% |
| Safety | ||||
| Net Debt / EBITDA | 4.69 | 2.53 | 3.27 | 4.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -246.53 | 6.37 | 11.12 | 14.91 |